Astec Lifesciences Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats| Big Deal (Insider and SAST) sells last month greater than 1% of total shares | |
| Promoter holding decreased by more than -2% QoQ | -5.3% returns for over 0.2 years |
| Inefficient use of capital to generate profits - RoCE declining in the last 2 years | -9.0% returns for Nifty 500 over 1.9 years |
| Promoter decreasing their shareholding |
| Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE | |
| Positive Breakout First Resistance ( LTP > R1) | |
| 30 Day SMA crossing over 200 Day SMA, and current price greater than open | 34.5% returns for Nifty 500 over 1.2 years |
| High Momentum Scores (Technical Scores greater than 50) | 319.5% returns for Nifty 500 over 5.1 years |
| Negative to Positive growth in Sales and Profit with Strong Price momentum | |
| Highest Recovery from 52 Week Low |
| Stocks with Expensive Valuations according to the Trendlyne Valuation Score | 177.2% returns for Nifty 500 over 4.5 years |
| Increasing Trend in Non-Core Income |
| Expensive Performers (DVM) | 102.3% returns for over 5.4 years |
| Expensive Performers (DVM) | 79.4% returns for over 5.4 years |
| Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks | 181.7% returns for Nifty 500 over 4.5 years |
| RSI indicating price weakness | |
| Top Gainers |
